Cardio Diagnostics Holdings (CDIO) Cash from Investing Activities (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Cash from Investing Activities of -$63696.0 for Q1 2026, up 18.71% sequentially from -$78359.0 in Q4 2025, and down 34.34% YoY from -$97004.7 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Cash from Investing Activities for 6 years, with the latest figure at -$63696.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 34.34% year-over-year to -$63696.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$435591.0 (down 14.13% YoY) and the FY2025 annual result came in at -$419310.0, down 3.74% from the prior year.
- Cash from Investing Activities improved to -$63696.0 in Q1 2026 per CDIO's latest filing, from -$78359.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$2512.0 in Q4 2022 and troughed at -$566948.0 in Q4 2023.
- A 5-year average of -$120558.1 and a median of -$69941.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 100.0% in 2022, then slumped 22469.59% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$2512.0 in 2022, then plunged by 22469.59% to -$566948.0 in 2023, then soared by 90.37% to -$54613.0 in 2024, then slumped by 43.48% to -$78359.0 in 2025, then grew by 18.71% to -$63696.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$63696.0, -$78359.0, and -$257819.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | -46,789.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46,789.00 |
| Jun 30, 2026 | -46,789.00 |
| Mar 31, 2026 | -63,696.00 |
| Mar 31, 2026 | -63,696.00 |
| Dec 31, 2025 | -78,359.00 |
| Dec 31, 2025 | -78,359.00 |
| Sep 30, 2025 | -257,819.00 |
| Sep 30, 2025 | -257,819.00 |
| Jun 30, 2025 | -35,717.00 |
| Jun 30, 2025 | -35,717.00 |
| Mar 31, 2025 | -47,415.00 |
| Mar 31, 2025 | -47,415.00 |
| Dec 31, 2024 | -54,613.00 |
| Dec 31, 2024 | -54,613.00 |
| Sep 30, 2024 | -78,567.00 |
| Sep 30, 2024 | -78,567.00 |
| Jun 30, 2024 | -201,069.00 |
| Jun 30, 2024 | -201,069.00 |
| Mar 31, 2024 | -69,941.00 |
| Mar 31, 2024 | -69,941.00 |